Bertrand Ndzelen's Colleagues at Sysmex Inostics
Bertrand Ndzelen's Contact Details
443-759-8650
Sysmex Inostics
Bertrand Ndzelen's Company Details
Leaders of the Global Liquid Biopsy RevolutionAs pioneers in blood-based cell-free tumor DNA (ctDNA) mutation detection, Sysmex Inostics has provided custom assays and CLIA-certified lab services to leading BioPharma companies over the last 10 years with the overall goal: to develop therapeutics that extend lives and provide diagnostics to monitor response to therapy, identify targetable resistance alterations, and detect minimal residual disease (MRD).SafeSEQ NGS technology can detect clinically relevant mutations in circulating tumor DNA (ctDNA) with robust detection as low as 0.03% mutant allele frequency (MAF), thus ensuring reliable molecular information for real-time therapy selection as well as monitoring of tumor response from across a broader range of genomic regions.